BR112012013035A8 - Fibronectina: quimeras do fator do crescimento - Google Patents
Fibronectina: quimeras do fator do crescimentoInfo
- Publication number
- BR112012013035A8 BR112012013035A8 BR112012013035A BR112012013035A BR112012013035A8 BR 112012013035 A8 BR112012013035 A8 BR 112012013035A8 BR 112012013035 A BR112012013035 A BR 112012013035A BR 112012013035 A BR112012013035 A BR 112012013035A BR 112012013035 A8 BR112012013035 A8 BR 112012013035A8
- Authority
- BR
- Brazil
- Prior art keywords
- fibronectin
- growth factor
- protein complexes
- chimers
- igf
- Prior art date
Links
- 108010067306 Fibronectins Proteins 0.000 title abstract 5
- 239000003102 growth factor Substances 0.000 title abstract 4
- 102000016359 Fibronectins Human genes 0.000 title 1
- 102100037362 Fibronectin Human genes 0.000 abstract 4
- 102000007474 Multiprotein Complexes Human genes 0.000 abstract 3
- 108010085220 Multiprotein Complexes Proteins 0.000 abstract 3
- 238000011282 treatment Methods 0.000 abstract 2
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 abstract 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 1
- 102100028071 Fibroblast growth factor 7 Human genes 0.000 abstract 1
- 108090000385 Fibroblast growth factor 7 Proteins 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 abstract 1
- 102000004218 Insulin-Like Growth Factor I Human genes 0.000 abstract 1
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 abstract 1
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 101710098940 Pro-epidermal growth factor Proteins 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000012292 cell migration Effects 0.000 abstract 1
- 230000004663 cell proliferation Effects 0.000 abstract 1
- 239000002537 cosmetic Substances 0.000 abstract 1
- 230000010393 epithelial cell migration Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 230000004936 stimulating effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/50—Fusion polypeptide containing protease site
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US12/627,647 US20100143442A1 (en) | 2003-02-05 | 2009-11-30 | Growth factor complexes and modulation of cell migration and growth |
| US12/793,386 US8871709B2 (en) | 2003-02-05 | 2010-06-03 | Synthetic chimeric proteins comprising epidermal growth factor and vitronectin |
| PCT/AU2010/001613 WO2011063477A1 (en) | 2009-11-30 | 2010-11-30 | Fibronectin: growth factor chimeras |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112012013035A2 BR112012013035A2 (pt) | 2017-05-16 |
| BR112012013035A8 true BR112012013035A8 (pt) | 2018-04-03 |
Family
ID=44065756
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112012013035A BR112012013035A8 (pt) | 2009-11-30 | 2010-11-30 | Fibronectina: quimeras do fator do crescimento |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2507261B1 (https=) |
| JP (1) | JP2013511960A (https=) |
| KR (1) | KR101930916B1 (https=) |
| CN (1) | CN102725308A (https=) |
| AU (1) | AU2010324554B2 (https=) |
| BR (1) | BR112012013035A8 (https=) |
| CA (1) | CA2781474C (https=) |
| ES (1) | ES2619938T3 (https=) |
| NZ (1) | NZ600454A (https=) |
| RU (1) | RU2012127364A (https=) |
| WO (1) | WO2011063477A1 (https=) |
| ZA (1) | ZA201203915B (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8871709B2 (en) | 2003-02-05 | 2014-10-28 | Queensland University of Technolgy | Synthetic chimeric proteins comprising epidermal growth factor and vitronectin |
| CN103834664B (zh) * | 2014-03-27 | 2016-05-04 | 吉林大学 | 重组表皮生长因子egf及其制备方法 |
| IL266023B2 (en) * | 2016-10-14 | 2024-07-01 | Neomatrix Therapeutics Inc | Peptides Derived from Fibronectin with Improved Bioactivity and Reduced Susceptibility to Neutrophil Elastase Degradation for Use in Treating Wounds |
| WO2019010533A1 (en) * | 2017-07-12 | 2019-01-17 | Factor Therapeutics Limited | TREATMENT OF OCULAR DISORDERS |
| CN110123732A (zh) * | 2019-04-03 | 2019-08-16 | 广州市拉凯尔干细胞研究所 | 一种含有纤连蛋白化妆品原料制备方法 |
| JP7791715B2 (ja) * | 2019-04-05 | 2025-12-24 | 韓國セラミック技術院 | Ｃｓｑ－タグを用いたタンパク質の発現及び精製方法 |
| KR102440312B1 (ko) * | 2020-08-28 | 2022-09-05 | 한국해양과학기술원 | 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도 |
| CN119264240B (zh) * | 2024-09-10 | 2025-03-25 | 浙江诸暨聚源生物技术有限公司 | 功能增强的重组纤连蛋白及其制备方法和应用 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4843000A (en) | 1979-12-26 | 1989-06-27 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
| US4849338A (en) | 1982-07-16 | 1989-07-18 | Syntex (U.S.A.) Inc. | Simultaneous calibration heterogeneous immunoassay |
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5091513A (en) | 1987-05-21 | 1992-02-25 | Creative Biomolecules, Inc. | Biosynthetic antibody binding sites |
| CA1341598C (en) | 1988-07-15 | 2009-09-29 | Central Sydney Area Health Service | Acid-labile sub-unit (als) of insulin-like growth factor binding proteincomplex |
| US6090790A (en) | 1989-12-14 | 2000-07-18 | Eriksson; Elof | Gene delivery by microneedle injection |
| JP2866134B2 (ja) * | 1990-02-05 | 1999-03-08 | 寳酒造株式会社 | 機能性ポリペプチド |
| AU649066B2 (en) | 1990-07-25 | 1994-05-12 | Syngene, Inc. | Circular extension for generating multiple nucleic acid complements |
| US6054122A (en) | 1990-11-27 | 2000-04-25 | The American National Red Cross | Supplemented and unsupplemented tissue sealants, methods of their production and use |
| JP2829405B2 (ja) * | 1991-10-14 | 1998-11-25 | 寳酒造株式会社 | 機能性ポリペプチド |
| US5958764A (en) | 1992-04-30 | 1999-09-28 | Baylor College Of Medicine | Specific expression vectors and methods of use |
| AU6136694A (en) | 1993-02-12 | 1994-08-29 | Repligen Corporation | Methods for generating broadly neutralizing anti-hiv antibodies and antigens capable of eliciting same |
| US5422252A (en) | 1993-06-04 | 1995-06-06 | Becton, Dickinson And Company | Simultaneous amplification of multiple targets |
| US5962427A (en) | 1994-02-18 | 1999-10-05 | The Regent Of The University Of Michigan | In vivo gene transfer methods for wound healing |
| AUPM672594A0 (en) | 1994-07-08 | 1994-08-04 | Royal Children's Hospital Research Foundation | A method for the prophylaxis and/or treatment of proliferative and/or inflammatory skin disorders |
| JP3351471B2 (ja) * | 1994-11-29 | 2002-11-25 | タカラバイオ株式会社 | 形質転換細胞の製造方法 |
| KR100353115B1 (ko) * | 1995-11-13 | 2003-01-06 | 다카라츠죠 가부시키가이샤 | 레트로바이러스를사용한표적세포내로의유전자도입방법 |
| DK0862656T3 (da) | 1995-11-21 | 2001-04-09 | Univ Yale | Unimolekylær segmentamplifikation og -detektering |
| US5752019A (en) | 1995-12-22 | 1998-05-12 | International Business Machines Corporation | System and method for confirmationally-flexible molecular identification |
| US5835382A (en) | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
| US6077987A (en) | 1997-09-04 | 2000-06-20 | North Shore-Long Island Jewish Research Institute | Genetic engineering of cells to enhance healing and tissue regeneration |
| AU3192299A (en) | 1998-03-18 | 1999-10-11 | Wake Forest University | Improved implantable biomaterials, compositions and methods for their preparation and uses thereof |
| AUPP298498A0 (en) | 1998-04-17 | 1998-05-07 | Gropep Pty Ltd | Matrix binding factor |
| US6436897B2 (en) | 1998-06-01 | 2002-08-20 | Celtrix Pharmaceuticals, Inc. | Pharmaceutical formulations for IGF/IGFBP |
| AU3897200A (en) | 1999-03-18 | 2000-10-04 | Hope Heart Institute, The | Endothelial cell stimulation by a complex of fibronectin and vascular endothelial growth factor |
| AU2003900481A0 (en) * | 2003-02-05 | 2003-02-20 | Queensland University Of Technology | Synthetic modulators of cell migration and growth |
| JP2008125460A (ja) * | 2006-11-22 | 2008-06-05 | Institute Of Physical & Chemical Research | フィブリン結合性成長因子 |
| WO2008157483A2 (en) * | 2007-06-14 | 2008-12-24 | The Research Foundation Of State University Of New York | Polypeptides and methods of use |
-
2010
- 2010-11-30 CN CN201080062313XA patent/CN102725308A/zh active Pending
- 2010-11-30 JP JP2012540231A patent/JP2013511960A/ja active Pending
- 2010-11-30 WO PCT/AU2010/001613 patent/WO2011063477A1/en not_active Ceased
- 2010-11-30 NZ NZ600454A patent/NZ600454A/en not_active IP Right Cessation
- 2010-11-30 AU AU2010324554A patent/AU2010324554B2/en not_active Ceased
- 2010-11-30 RU RU2012127364/10A patent/RU2012127364A/ru not_active Application Discontinuation
- 2010-11-30 BR BR112012013035A patent/BR112012013035A8/pt not_active Application Discontinuation
- 2010-11-30 EP EP10832439.3A patent/EP2507261B1/en not_active Not-in-force
- 2010-11-30 ES ES10832439.3T patent/ES2619938T3/es active Active
- 2010-11-30 CA CA2781474A patent/CA2781474C/en not_active Expired - Fee Related
- 2010-11-30 KR KR1020127016766A patent/KR101930916B1/ko not_active Expired - Fee Related
-
2012
- 2012-05-29 ZA ZA2012/03915A patent/ZA201203915B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2507261B1 (en) | 2016-12-21 |
| KR20120114277A (ko) | 2012-10-16 |
| AU2010324554A1 (en) | 2012-06-21 |
| CA2781474C (en) | 2019-06-18 |
| NZ600454A (en) | 2014-10-31 |
| KR101930916B1 (ko) | 2018-12-19 |
| EP2507261A4 (en) | 2013-04-10 |
| ZA201203915B (en) | 2018-11-28 |
| JP2013511960A (ja) | 2013-04-11 |
| RU2012127364A (ru) | 2014-01-10 |
| BR112012013035A2 (pt) | 2017-05-16 |
| CA2781474A1 (en) | 2011-06-03 |
| EP2507261A1 (en) | 2012-10-10 |
| WO2011063477A1 (en) | 2011-06-03 |
| CN102725308A (zh) | 2012-10-10 |
| ES2619938T3 (es) | 2017-06-27 |
| AU2010324554B2 (en) | 2014-07-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112012013035A8 (pt) | Fibronectina: quimeras do fator do crescimento | |
| BR112012030821A2 (pt) | vitronectina:fator de crescimento quimeras queratinócitos | |
| AU2003900481A0 (en) | Synthetic modulators of cell migration and growth | |
| Chun et al. | A synthetic cryptochrome inhibitor induces anti-proliferative effects and increases chemosensitivity in human breast cancer cells | |
| BR112012007239A2 (pt) | moléculas de ligação biespecíficas para terapia antiangiogênese | |
| CO6640289A2 (es) | Composiciones de anticuerpos anti-factor de crecimiento nervioso (ngf) | |
| AR054175A1 (es) | Nuevos anticuerpos anti-igf-ir y usos de los mismos | |
| CO6450656A2 (es) | Anticuerpos anti-tnf-alfa y sus usos | |
| BR112012004546A8 (pt) | Terapêutica por proteínas ligantes dll4-ligantes | |
| BR112012009432A2 (pt) | anticorpo anti-hsv | |
| AR079572A1 (es) | Anticuerpos que se enlazan a los epitopos de un polipeptido wise | |
| BR112012012918A2 (pt) | agente indutor de apoptose para o tratamento de câncer e de doenças imunes e autoimunes. | |
| BR112014015442A8 (pt) | compostos e composições para inibir a interação de bcl2 com parceiros de ligação | |
| NI201500002A (es) | Agentes de unión de rspo3 y usos de los mismos. | |
| CO7131381A2 (es) | Usos terapeúticos de proteínas del factor de crecimiento del fibroplasto | |
| EP3747457A3 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| EA201990839A1 (ru) | Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками 158p1d7 | |
| BR112014031788A2 (pt) | composições e métodos para o tratamento de diabetes | |
| BR112014015308A2 (pt) | compostos para inibição da interação de bcl2 com contrapartes de ligação | |
| BR112014015322A2 (pt) | compostos e composições para inibir a interação de bcl2 com parceiros de ligação | |
| GT200900126A (es) | Novedosos anticuerpos antiproliferacion | |
| BR112013010535A2 (pt) | composições direcionadas o domínio extracelular solúvel de e-caderina e métodos relacionados para terapia de câncer | |
| BR112014020885A2 (pt) | oligonucleotídeos para modulação da expressão gênica e seu uso | |
| MX376011B (es) | Peptidos promotores del crecimiento y usos de los mismos. | |
| MX339001B (es) | Proceso para la produccion de parches o apositos de piel autologa mediante cultivo de queratinocitos y fibroblastos autologos con suero autologo para generacion de piel. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25A | Requested transfer of rights approved |
Owner name: QUTBLUEBOX PTY LTD. (AU) |
|
| B25A | Requested transfer of rights approved |
Owner name: TISSUE THERAPIES LIMITED (AU) |
|
| B06F | Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette] | ||
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] |